Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07537010) titled '3D1015 Injection for Patients With mCRPC' on April 7.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Chunjing Yu

Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC

Intervention: Drug: Lu 177-PSMA-3D1015 Injection

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: August 27, 2025

Target Sample Size: 8

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07537010

Disclaimer: Curated by HT Syndication....